Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.

Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, Bartlett DL.

Cancer Gene Ther. 2000 Jan;7(1):66-73.

2.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

3.

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL.

Cancer Res. 2001 Dec 15;61(24):8751-7.

6.

Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.

Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.

Cancer Res. 2001 Apr 1;61(7):2983-95.

7.

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

Gnant MF, Noll LA, Irvine KR, Puhlmann M, Terrill RE, Alexander HR Jr, Bartlett DL.

J Natl Cancer Inst. 1999 Oct 20;91(20):1744-50.

PMID:
10528025
8.

Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues.

Takakuwa K, Fujita K, Kikuchi A, Sugaya S, Yahata T, Aida H, Kurabayashi T, Hasegawa I, Tanaka K.

Jpn J Cancer Res. 1997 Feb;88(2):166-75.

PMID:
9119745
9.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
10.

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.

Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM, Erbs P.

Gene Ther. 2008 Oct;15(20):1361-71. doi: 10.1038/gt.2008.82. Epub 2008 May 15.

PMID:
18480846
11.

HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.

Moriuchi S, Krisky DM, Marconi PC, Tamura M, Shimizu K, Yoshimine T, Cohen JB, Glorioso JC.

Gene Ther. 2000 Sep;7(17):1483-90.

12.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

13.

In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.

Peplinski GR, Tsung AK, Casey MJ, Meko JB, Fredrickson TN, Buller RM, Norton JA.

Cancer J Sci Am. 1996 Jan-Feb;2(1):21-7.

PMID:
9166494
16.

In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.

Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LW, Kao C.

Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80.

PMID:
9824046
17.

Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.

Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LW.

Cancer Res. 1996 Oct 15;56(20):4614-9.

18.

VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.

Qiao J, Moreno J, Sanchez-Perez L, Kottke T, Thompson J, Caruso M, Diaz RM, Vile R.

Gene Ther. 2006 Oct;13(20):1457-70. Epub 2006 May 25.

PMID:
16724095
19.

Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.

Shashkova EV, Cherenova LV, Kazansky DB, Doronin K.

Cancer Gene Ther. 2005 Jul;12(7):617-26.

PMID:
15761475

Supplemental Content

Support Center